NCT00072150 arm group c2a9f155c91ecc514c91976fd9685f8f [clinicaltrials_resource:NCT00072150/arm-group/c2a9f155c91ecc514c91976fd9685f8f]
NCT00072150 arm group c2a9f155c91ecc514c91976fd9685f8f [clinicaltrials_resource:NCT00072150/arm-group/c2a9f155c91ecc514c91976fd9685f8f]
Bio2RDF identifier
NCT00072150/arm-group/c2a9f155c91ecc514c91976fd9685f8f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a9f155c91ecc514c91976fd9685f8f
description [clinicaltrials_vocabulary:description]
Patients receive bortezomib IV ...... onal courses of study therapy.
identifier
clinicaltrials_resource:NCT00072150/arm-group/c2a9f155c91ecc514c91976fd9685f8f
title
NCT00072150 arm group c2a9f155c91ecc514c91976fd9685f8f
@en
type
label
NCT00072150 arm group c2a9f155 ...... 9f155c91ecc514c91976fd9685f8f]
@en